Brielan Smiechowski - ISpecimen Senior Development
| ISPC Stock | USD 4.22 0.07 1.69% |
Executive
Brielan Smiechowski is Senior Development of iSpecimen
| Address | 450 Bedford Street, Lexington, MA, United States, 02420 |
| Phone | 781 301 6700 |
| Web | https://ispecimen.com |
ISpecimen Management Efficiency
The company has return on total asset (ROA) of (0.4426) % which means that it has lost $0.4426 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0934) %, meaning that it created substantial loss on money invested by shareholders. ISpecimen's management efficiency ratios could be used to measure how well ISpecimen manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -1.36. The current year's Return On Capital Employed is expected to grow to -1.09. At present, ISpecimen's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.5 M, whereas Non Current Assets Total are forecasted to decline to about 4.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John PharmD | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| David Ege | Seres Therapeutics | 49 | |
| Lee Flowers | HCW Biologics | 78 | |
| Nicole Esq | HCW Biologics | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Caroline MD | Ikena Oncology | 52 | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Alexander Constan | Ikena Oncology | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| David MS | Ikena Oncology | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.44 |
iSpecimen Leadership Team
Elected by the shareholders, the ISpecimen's board of directors comprises two types of representatives: ISpecimen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ISpecimen. The board's role is to monitor ISpecimen's management team and ensure that shareholders' interests are well served. ISpecimen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ISpecimen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annette Arnold, Vice Development | ||
| Emily Hubbard, VP Devel | ||
| Benjamin Bielak, Chief Secretary | ||
| Eric Langlois, Chief Officer | ||
| Dawn Michelle, VP Operations | ||
| Tracy Curley, Treasurer CFO | ||
| Brielan Smiechowski, Senior Development | ||
| Carly Lejnieks, Vice Marketing | ||
| Leslie Hoyt, Senior Operations | ||
| Jill Mullan, S Director | ||
| David MD, Chief Officer | ||
| Evan Cox, Senior Innovation |
ISpecimen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ISpecimen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 3.5 M | ||||
| Shares Outstanding | 962.64 K | ||||
| Shares Owned By Insiders | 14.50 % | ||||
| Shares Owned By Institutions | 4.04 % | ||||
| Number Of Shares Shorted | 75.02 K | ||||
| Price To Earning | 0.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.12) | Revenue Per Share 19.19 | Quarterly Revenue Growth (0.04) | Return On Assets (0.44) | Return On Equity (1.09) |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.